Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

• Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery • FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for...
August 09, 2021 08:00 ET | Source: PolyPid Ltd.

PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021

PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,...
July 28, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021

PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,...
July 12, 2021 08:00 ET | Source: PolyPid Ltd.

PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director

PETAH TIKVA, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release...
June 23, 2021 06:30 ET | Source: PolyPid Ltd.

PolyPid Presents today at The Raymond James Human Health Innovation Conference

PETAH TIKVA, Israel, June 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,...
June 02, 2021 09:10 ET | Source: PolyPid Ltd.

PolyPid to Present at Upcoming Healthcare Investor Conferences

PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,...
May 19, 2021 08:00 ET | Source: PolyPid Ltd.

PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program

FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery. Enrollment in Phase 3 SHIELD I...
May 12, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update

• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three...
April 29, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021

PETAH TIKVA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,...
February 23, 2021 07:30 ET | Source: PolyPid Ltd.

PolyPid to Participate in Upcoming Investor Conferences

PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered,...